Sanofi agreed to buy Provention Bio Inc. in a $2.9 billion deal intended to bolster the French drugmaker's portfolio of diabetes medicines with a new therapy recently approved in the U.S.
In a social media landscape shaped by hashtags, algorithms, and viral posts, nurse leaders must decide: Will they let the narrative spiral, or can they adapt and join the conversation?
...
